Elaine R Mardis, AACR 2018 – Advances in Cancer Research and Translational Medicine
Elaine R Mardis from the Nationwide Children’s Hospital & Ohio State University College of Medicine, OH, US, and AACR President-Elect (2018–2019), talks to us about her upcoming role and how AACR aims to meet unmet needs in cancer research and personalized medicine in the future.
1. What are the main aims of the American Association for Cancer Research (AACR)? (0:08)
2. What do you anticipate to be the major challenges of your role as president of the AACR? (0:31)
3. What have been the most exciting developments in the genomic characterization of cancer in the past year? (1:35)
4. What are the major unmet needs in personalized cancer medicine? (2:19)
5. What do you expect to be the key themes of the AACR annual meeting? (3:24)Speaker disclosures: Elaine R Mardis has nothing to disclose in relation to this video interview.
Filmed at the American Association for Cancer Research (AACR) Annual Meeting 2018, Chicago, IL, US, April 14–18, 2018.
Share this Video
Related Videos In Haematological Malignancies
Massimo Breccia, ASH 2022: Asciminib for patients with chronic myeloid leukaemia, the ASC4OPT study
The ASC4OPT study aims to potentially optimize dosing levels of asciminib in patients with chronic myeloid leukaemia in the chronic phase that have previously been treated with 2 lines of tyrosine kinase inhibitors. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the ASCEMBL findings, what we […]
Massimo Breccia, ASH 2022: The limitations of tyrosine kinase inhibitors in chronic myeloid leukaemia and approval status of asciminib
Tyrosine kinase inhibitors (TKIs) are the standard of care in the treatment of chronic myeloid leukaemia (CML). Asciminib is the first BCR::ABL1 inhibitor that functions by specifically targeting the ABL myristoyl pocket. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the limitations of TKIs in the […]
Shaji Kumar, ASH 2022: Promising new agents enhancing the treatment of multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses some promising new agents for the treatment of multiple myeloma, including immunotherapies like CAR-T cell therapies, as well as data from novel bispecific antibodies in the context of relapsed or refractory multiple myeloma. Abstract 158: Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!